Tag: Auranofin

Ridaura (auranofin) is an oral gold compound used to treat active rheumatoid arthritis when other therapies are insufficient. Like other gold-containing drugs, it carries a risk of significant toxicity, making it crucial for patients and healthcare providers to understand what are the contraindications for Ridaura. This article details the specific conditions and drug interactions that prevent its safe use.

As a gold compound used to treat rheumatoid arthritis, Ridaura (auranofin) carries a range of potential side effects, with some occurring in nearly half of patients. Understanding the nature of **what are the side effects of Ridaura** is crucial for anyone considering or undergoing this form of therapy, as they can range from common gastrointestinal issues to rare, but severe, systemic toxicities.

Initially approved in 1985, the oral gold compound Ridaura, or auranofin, was a key development in treating rheumatoid arthritis. However, the drug's exact mechanism is not fully understood, and today, it is rarely used for its original purpose due to the availability of more potent therapies. To understand how does Ridaura work, one must explore its complex pharmacological effects, which focus on immunomodulation and key enzyme inhibition.